Predict your next investment

Venture Capital
alafi.com

See what CB Insights has to offer

Investments

46

Portfolio Exits

13

Service Providers

1

About Alafi Capital

Alafi Capital is a private venture capital firm that has been active in healthcare investing for over 25 years. Early and mid-stage investments in the U.S. and Europe are considered, with emphasis on product-oriented biotechnology, life science technologies, imaging and diagnostics, and medical devices. Included among Alafi Capital's past successes are Amgen, Biogen, Molecular Devices, Tanox, Qiagen, Novocor, Oxford Glycosciences, and Applied Biosystems.

Alafi Capital Headquarter Location

1333 Jones St., #1702

San Francisco, California, 94109,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Alafi Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Alafi Capital in 3 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

I

Industrial SynBio

382 items

Synthetic biology focused on replacing industrial and commercial materials.

Latest Alafi Capital News

Edifice Health Raises $12M in Funding

Apr 26, 2021

Edifice Health , a San Mateo, CA-based immunological health and personalized nutrition company, raised $12m in funding. The round was led by Leaps by Bayer with participation from Paladin Capital Group, Vertical Venture Partners, Ahren Innovation Capital, Ataraxia Capital Partners, Shanda Grab Ventures, Alafi Capital, and Taisho Pharmaceutical. Seed stage investors include Human Longevity and Performance Impact Venture Fund, Longevity Incubator Fund, Summer Venture Capital, Carlyle Global Advisors, M4 Capital GmbH, and Better Food Ventures. Leaps by Bayer’s Naveen Krishnan, MD, MPhil, and Paladin Group’s Paul Conley, PhD, will join Edifice’s Board of Directors, alongside Santosh Padki, a San Francisco-based consumer products veteran, and David Furman, PhD, Edifice Founder, Leader of the Stanford Project, and Associate Professor of Applied Artificial Intelligence in Systems and Computational Immunology of Aging at the Buck Institute for Research on Aging. The company intends to use the funds to grow its foundation of immunological science and add additional talent. Led by Wolfgang Daum, PhD, Chairman and CEO, and a serial life science entrepreneur, Edifice uses novel proteomic approaches and combines them with proprietary artificial intelligence and predictive analysis to measure the rate at which an individual’s body ages. The company has created a metric to measure systemic chronic inflammation, which, the Stanford Project research showed to be the root cause – and thus, the predictor – of multiple chronic diseases of aging. Furthermore, the company has identified interventional supplements, which can be targeted to an individual’s immunotype to improve inflammatory health and facilitate healthy aging. Edifice was born out of the Stanford 1,000 Immunomes’ Project, following the 10-year National Institute of Health-funded research in immunological health and aging at Stanford University. FinSMEs 26/04/2021

Alafi Capital Investments

46 Investments

Alafi Capital has made 46 investments. Their latest investment was in Edifice Health as part of their Series B on April 4, 2021.

CBI Logo

Alafi Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/26/2021

Series B

Edifice Health

$12M

Yes

Ahren Innovation Capital, Ataraxia Capital Partners, Better Foods, Human Longevity, Impact Venture Capital, Leaps by Bayer, M4Capital, Paladin Capital Group, Shanda Group, Summer Venture Capital, Taisho Pharmaceutical, The Carlyle Group, The Longevity Fund, and Vertical Venture Partners

3

12/10/2020

Series A

Resolve Biosciences

$24M

Yes

High-Tech Grunderfonds, John Shoffner, MasterMind Advisory Services, and PS Capital Partners

2

12/28/2015

Series C

Bolt Threads

$50M

No

East-West Capital Partners, Formation 8, Founders Fund, Innovation Endeavors, Nan Fung, and Zygote Ventures

6

6/4/2015

Series B

Subscribe to see more

$99M

Subscribe to see more

10

6/19/2013

Series F - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/26/2021

12/10/2020

12/28/2015

6/4/2015

6/19/2013

Round

Series B

Series A

Series C

Series B

Series F - II

Company

Edifice Health

Resolve Biosciences

Bolt Threads

Subscribe to see more

Subscribe to see more

Amount

$12M

$24M

$50M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Ahren Innovation Capital, Ataraxia Capital Partners, Better Foods, Human Longevity, Impact Venture Capital, Leaps by Bayer, M4Capital, Paladin Capital Group, Shanda Group, Summer Venture Capital, Taisho Pharmaceutical, The Carlyle Group, The Longevity Fund, and Vertical Venture Partners

High-Tech Grunderfonds, John Shoffner, MasterMind Advisory Services, and PS Capital Partners

East-West Capital Partners, Formation 8, Founders Fund, Innovation Endeavors, Nan Fung, and Zygote Ventures

Sources

3

2

6

10

10

Alafi Capital Portfolio Exits

13 Portfolio Exits

Alafi Capital has 13 portfolio exits. Their latest portfolio exit was NxThera on March 21, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/21/2018

Acquired

$991

4

8/4/2016

Acquired

$991

Myriad Genetics

1

6/13/2016

Acq - Fin

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

3/21/2018

8/4/2016

6/13/2016

00/00/0000

00/00/0000

Exit

Acquired

Acquired

Acq - Fin

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Myriad Genetics

Subscribe to see more

Subscribe to see more

Sources

4

1

1

10

10

Alafi Capital Service Providers

1 Service Provider

Alafi Capital has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

Alafi Capital Team

3 Team Members

Alafi Capital has 3 team members, including current Chief Financial Officer, Bill Weiss.

Name

Work History

Title

Status

Bill Weiss

Chief Financial Officer

Current

Moshe H. Alafi

General Partner

Current

Christopher D. Alafi

General Partner

Current

Name

Bill Weiss

Moshe H. Alafi

Christopher D. Alafi

Work History

Title

Chief Financial Officer

General Partner

General Partner

Status

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.